Distinct Mechanisms Responsible for the Increase in Glucose Production and Ketone Formation Caused by Empagliflozin in T2DM Patients
Authors' conclusion
The decrease in plasma insulin and increase in plasma glucagon concentration caused by empagliflozin is responsible for the increase in plasma FFA concentration and ketone production. The increase in EGP caused by empagliflozin is independent of the change in plasma insulin or glucagon concentrations and is likely explained by the increase in NE turnover.
Study context
- Population
- Subjects with T2DMtwo studies, random order
- Participants
- 12 subjects
- Comparison
- Empagliflozin 25 mg vs placebo, under fasting and pancreatic clamp conditions
- Empagliflozinn = 8
- Placebon = 4reference
- Outcome
- Effects of empagliflozin
Methodological detailsrandomised order, placebo-controlled, pancreatic clamp
- Randomised order
- Placebo-controlled
- Pancreatic clamp
Main finding
As reported in the abstract
- Fasting: Endogenous glucose production (EGP) increase
- 31%
- Fasting: change in plasma glucose
- −34 mg/dL
- Fasting: change in insulin
- −52%
- Fasting: increase in plasma glucagon
- +19%
- Fasting: increase in free fatty acid (FFA)
- +29%
- Fasting: increase in β-hydroxybutyrate
- +48%
- Total-body norepinephrine (NE) turnover rate greater with empagliflozin vs placebo under fasting and clamp conditions
- +67%
Original publication
Distinct Mechanisms Responsible for the Increase in Glucose Production and Ketone Formation Caused by Empagliflozin in T2DM Patients. Diabetes Care. Published 1 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →